Bra podd

Sebastian Stintzing, MD - A Step-by-Step Guide to Metastatic CRC: Strategies to Integrate Anti-EGFR Therapies

13 augusti | 22 min

Daniel Petrylak, MD - Answering Key Questions About Biomarkers in Urothelial Cancer: Guidance for Improving Implementation

31 juli | 20 min

Benjamin Levy, MD, FASCO - Keeping Pace With TROP2-Directed ADCs: Their Evolving Role in Advanced, Pretreated EGFR-Mutated NSCLC

29 juli | 15 min

Luis Paz-Ares, MD, PhD / Niels Reinmuth, MD, PhD - Developing a Master Plan for ES-SCLC: A Practical Guide to Elevate Care in the Real-World

28 juli | 28 min

John Marshall, MD - Re-Invigorating the Later-Line Treatment of Metastatic Colorectal Cancer: Practical Strategies to Optimize the Use of Tyrosine Kinase Inhibitors

18 juli | 23 min

Neil D. Gross, MD, FACS - Evolving the Multi-Modal Approach for Resectable Cutaneous Squamous Cell Carcinoma: A Multidisciplinary Assessment of Current and Emerging Immunotherapeutic Strategies

11 juli | 69 min

Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations

7 juli | 23 min

Selim Corbacioglu, MD, PhD - Transforming Transfusion Dependence: Practical Steps for Incorporating Novel Beta Thalassemia Treatments Into Practice

4 juli | 16 min

Thomas Powles, MBBS, MRCP, MD / Jonathan E. Rosenberg, MD - Advancing Urothelial Carcinoma Care With Multidisciplinary Strategies for Clinical Management

3 juli | 68 min

Barbara Burtness, MD - The Pan-Tumor Perspective: Looking Toward the Future of Care With HER3-Directed ADCs for Pretreated Patients With Advanced Solid Tumors

1 juli | 12 min

Mark A. Socinski, MD - Global Perspectives on Biomarker Testing in NSCLC: Clinical Insights on Optimizing Implementation in Practice

24 juni | 13 min

Venkataraman Raman Muthusamy, MD, MAS - A Window of Opportunity: Identifying the Risk of Esophageal Adenocarcinoma With Prognostic Testing

23 juni | 17 min

Aditya Bardia, MD / Joyce O'Shaughnessy, MD - Optimizing Survivorship Across the Patient Journey, Including Lines of Therapy

17 juni | 20 min

Aditya Bardia, MD / Giuseppe Curigliano, MD, PhD - Sequencing in the Real World With Complex Patient Types, Including Underrepresented Populations

2 juni | 21 min

Aditya Bardia, MD / Joyce O'Shaughnessy, MD - Expert-Guided Approaches to Sequencing Strategies With ADCs in HR+, HER2- mBC

29 maj | 27 min

Jesus G. Berdeja, MD - Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma With Bispecific Antibodies: A Community Clinician's Roadmap

6 maj | 17 min

Aditya Bardia, MD / Sara Hurvitz, MD - Making a World of Difference for Patients With HER2-Low and -Ultralow Advanced Breast Cancer: Practical Strategies to Integrate Antibody-Drug Conjugates in Special Populations

16 april | 30 min

Komal Jhaveri, MD, FACP - Opportunities to Personalize Care: Making the Case for TROP2-Directed ADCs in HR+, HER2- Metastatic Breast Cancer

10 april | 19 min

Aditya Bardia, MD / Sara Hurvitz, MD - Realizing the Potential of Antibody-Drug Conjugates in HER2-Low and -Ultralow Advanced Breast Cancer: Evolving Strategies to Individualize Care

10 april | 26 min

Aditya Bardia, MD / Marilyn M. Bui, MD, PhD - Bringing HER2 Low and Ultralow to Light: How to Define and Detect HER2 Status in Advanced Breast Cancer

4 april | 22 min

Thomas Martin, MD - Focusing on the Frontline: The Impact of Anti-CD38-Based Quadruplet Regimens for Transplant-Ineligible, Newly-Diagnosed Myeloma

7 mars | 15 min

Arvind Dasari, MD - Leveling Up Care in the Later-Line Treatment of Metastatic Colorectal Cancer: Bringing Quality of Life to the Forefront

31 januari | 14 min

Jorge Cortes, MD / Elias Jabbour, MD - Care Strategies for Chronic Myeloid Leukemia in Chronic Phase: Customizing Frontline TKI Therapy to Optimize Long-term Patient Outcomes

8 januari | 16 min

Joshua Richter, MD, FACP - Enhancing Outcomes in Heavily Pretreated Relapsed/Refractory Multiple Myeloma: Harnessing Bispecific Antibodies in Community Care

8 januari | 14 min

Pasi A. Jänne, MD, PhD - Expanding Pathways of Care for HER2-Positive Metastatic NSCLC: Beyond Mutation to Overexpression

2 januari | 14 min

Aditya Bardia, MD - Keeping Pace With TROP2-Directed ADCs in HR-Positive, HER2-Negative/Low Advanced Breast Cancer

31 december 2024 | 14 min

Sangini S. Sheth, MD, MPH - The Power of Prevention: Patient-Clinician Insights on Increasing HPV Vaccination Uptake to Reduce Cervical Cancer Risk

27 december 2024 | 19 min

Sunandana Chandra, MD, MS - Practical Guidance on Managing Adverse Events Associated With Immunotherapy Regimens for Nonmelanoma Skin Cancers

17 december 2024 | 14 min

Alexander I. Spira, MD, PhD, FACP - Biomarkers at the Forefront: The Crucial Role of Testing Across Solid Tumor Types

13 december 2024 | 15 min

David Harpole, MD / Alfredo Addeo, MD - The Possibilities of Perioperative: Assessing the Use of Perioperative Immunotherapy for Resectable NSCLC

12 december 2024 | 1 min

Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Advancing Care in EGFR-Mutated NSCLC: Unveiling New Horizons With ADCs

2 december 2024 | 33 min

David Harpole, MD / Neel Chudgar, MD - The Practicalities of Perioperative Immunotherapy for Resectable NSCLC

26 november 2024 | 24 min

David Harpole, MD / Nicolas Girard, MD, PhD - Trials and Tribulations: Examining the Data for Perioperative Immunotherapeutic Approaches in Resectable NSCLC

20 november 2024 | 31 min

Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Leveraging Precise Targets to Elevate Outcomes: NSCLC Treatment Strategies for HER2-Directed ADCs

15 november 2024 | 27 min

Jia Ruan, MD, PhD - Clinical Case Challenges in Frontline PTCL: Navigating the Landscape of CD30-Positive PTCL Treatment

15 november 2024 | 19 min

Nikhil I. Khushalani, MD - Practical Guidance for Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: Using Immunotherapy Effectively in Clinical Practice

6 november 2024 | 16 min

Jacob Sands, MD / Raffaele Califano, MD - Novel ADC Targets in Advanced NSCLC: Examining Emerging Strategies for TROP2-Directed ADCs

30 oktober 2024 | 27 min

Vishal A. Patel, MD - Selecting and Sequencing Systemic Treatment for Advanced Basal Cell Carcinoma

28 oktober 2024 | 14 min

Richard Kim, MD / Gerald Prager, MD - Evidence-Based Strategies for Optimizing Long-Term Treatment Responses in Later Lines of mCRC Care

28 oktober 2024 | 17 min

Ahmad Tarhini, MD, PhD - Adjuvant Approaches in High-Risk, Resectable Melanoma: A Practical Guide to Improving Outcomes With Immunotherapy-Based Regimens

19 september 2024 | 14 min

Joyce O'Shaughnessy, MD - Harnessing Immunotherapy for Early Breast Cancer Management: Neoadjuvant Updates in HR-Positive, HER2-Negative Disease

19 september 2024 | 15 min

David M. Miller, MD, PhD / Todd Schlesinger, MD - A Clinician’s Roadmap to Improving Outcomes in Advanced Basal Cell Carcinoma: Guiding Principles for the Use of Immunotherapies

13 september 2024 | 16 min

Mark Awad, MD, PhD - Advancing the Therapeutic Landscape of SCLC with B7-H3–Targeted Antibody-Drug Conjugates: Insights and Future Directions

9 september 2024 | 13 min

Vasu Divi, MD, MS - Neoadjuvant Immunotherapy for CSCC: Practical Considerations for Resectability, Patient Selection, and Treatment Optimization

9 september 2024 | 13 min

John L. Marshall, MD - Proactive Safety Management Strategies to Extend Survival for Patients With Metastatic CRC

9 augusti 2024 | 15 min

Aditya Bardia, MD - From Theory to Practice: Enhancing Antibody-Drug Conjugate Integration in HER2-Low Advanced Breast Cancer

9 augusti 2024 | 19 min

Rami Komrokji, MD - Navigating the First-Line Treatment Landscape of Anemia in Lower-Risk MDS: Translating the Latest Data to Practice

5 augusti 2024 | 13 min

Stephanie E. Combs, MD / Heather Wakelee, MD - A Growing Need for Targeted Approaches in Unresectable Stage III NSCLC: A Clinical Evaluation of Evolving Data in EGFR Mutation–Positive Disease

5 augusti 2024 | 16 min

Chris Verslype, MD, PhD - Optimizing TKI Therapy for Individualized Advanced HCC Treatment: Taking a Real-World Perspective

12 juli 2024 | 25 min

Luis Paz-Ares, MD, PhD - Exploring the Potential of TROP2 ADCs for Advanced/Metastatic NSCLC: Implications for Practice

12 juli 2024 | 12 min

Ticiana Leal, MD - Squaring Off With Squamous NSCLC: The Latest Evidence and Guidance on Chemoimmunotherapy Options

4 juli 2024 | 19 min

Ghassan Abou-Alfa, MD, MBA - Getting On the Right Tract: Patient-Centered Strategies to Diagnose Biliary Tract Cancers

4 juli 2024 | 12 min

Paul Telfer, MA, DM, BM, BCh, FRCP, FRCPath - Decoding the Future: Bringing Gene Therapy Into Prime Time for Patients With Sickle Cell Disease

4 juli 2024 | 13 min

Sagar Lonial, MD, FACP - Accelerating Targeted Degradation in Multiple Myeloma: The Role of CELMoDs in Overcoming IMiD Resistance in Earlier Lines of Therapy

4 juli 2024 | 14 min

Ben Carpenter, MD, PhD - Exploring Novel Therapeutic Frontiers in Transfusion-Dependent Beta Thalassemia: The Path to Transfusion Independence

25 juni 2024 | 14 min

Saad Z. Usmani, MD, MBA, FACP, FASCO - Making the Case for Triple Therapy in R/R Multiple Myeloma: Expert Guidance for Optimizing Anti-CD38 mAb Regimens

25 juni 2024 | 15 min

Josep M. Llovet, MD, PhD - Redefining How to Treat Intermediate-Stage HCC: Exploring TACE Plus Immunotherapy–Based Combination Therapy

18 juni 2024 | 13 min

Richard Kim, MD - Enhancing Treatment Sequencing to Extend Survival: Tailoring Later-Line Care to the Patient With Metastatic Colorectal Cancer

28 maj 2024 | 15 min

Jyoti Mayadev, MD - From Routine Screening to Applying Clinical Advances in Locally Advanced Cervical Cancer: Evolving Care in High-Risk Populations

30 april 2024 | 15 min

Peter Lio, MD - AI in Healthcare: A Primer for the Practicing Clinician

5 april 2024 | 14 min

Peter Lio, MD - Generative AI: Benefits for Your Practice, for Your Patients

5 april 2024 | 13 min

Geoffrey Ku, MD, MBA - Conversations in Precision Oncology: Harnessing Testing to Drive Personalized Treatment in HER2-Positive Advanced Gastric Cancer

5 april 2024 | 14 min

Martin C. Mahoney, MD, PhD - Reducing the Burden of HPV-Related Cancers: Strategies for Improving HPV Vaccine Uptake in Males

29 mars 2024 | 16 min

Aditya Bardia, MD - Endocrine Sensitivity in the Real World: Practical Guidance to Optimize Second-Line Care in ER-Positive, HER2-Negative Advanced Breast Cancer

29 mars 2024 | 20 min

Laura Spring, MD - The Patient-Clinician Alliance to Enhance Care for Patients With Metastatic Breast Cancer on Antibody-Drug Conjugates

25 mars 2024 | 15 min

Heather Wakelee, MD - Stepping Up Clinical Outcomes for Resectable NSCLC: Examining the Role of Neoadjuvant Plus Adjuvant Immunotherapy Regimens

14 mars 2024 | 14 min

Sue S. Yom, MD, PhD - Latest Updates in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Clinical Potential of Inhibitor of Apoptosis Protein (IAP) Antagonists to Change the Treatment Landscape

8 mars 2024 | 14 min

Steven M. Horwitz, MD - Advancing The Treatment Paradigm in Relapsed/Refractory B- and T-Cell Lymphoma: The Evolving Role of EZH1/2 Pathway Inhibitors

6 mars 2024 | 14 min

Nikhil I. Khushalani, MD - Pointing the Way to Enhanced Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Practical Strategies to Incorporate Neoadjuvant Immunotherapy

26 februari 2024 | 18 min

Stephen M. Ansell, MD, PhD / Caron Jacobson, MD, MMSc - Navigating a New Treatment Algorithm for Patients With Relapsed/Refractory Follicular Lymphoma: Where Do CD20 x CD3 Bispecific Antibodies Fit In?

26 februari 2024 | 16 min

Susana M. Campos, MD, MPH - Expanding the Potential of HER2-Directed Antibody-Drug Conjugates: Evidence and Application in New Tumor Types

22 februari 2024 | 18 min

John N. Allan, MD - Enhancing Patient Outcomes in Relapsed/Refractory Follicular Lymphoma: Recognizing the Role of Novel Bispecific Antibody–Based Therapies

14 februari 2024 | 15 min

Evan J. Lipson, MD - Real Talk About Maximizing Care in Advanced Melanoma: Balancing Benefit and Risk Using Dual Immunotherapy Regimens

14 februari 2024 | 13 min

Peter R. Galle, MD, PhD - Assembling a Long-Term Sequential Plan for Unresectable HCC: Practical Guidance for Improving Real-World Outcomes

10 januari 2024 | 23 min

David M. Miller, MD, PhD / Kevin Emerick, MD - Coming Together to Improve Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Multidisciplinary Care Strategies With Neoadjuvant Immunotherapy

3 januari 2024 | 14 min

Tanya Siddiqi, MD - Addressing Patient Needs With CAR T-Cell Therapy in the Treatment of CLL/SLL: Preparing for an Evolving Treatment Paradigm

3 januari 2024 | 14 min

Manish A. Shah, MD - Keeping Current on Frontline Immunotherapy-Chemotherapy Combinations: HER2-Positive and HER2-Negative Unresectable Advanced Gastric or GEJ Adenocarcinoma

29 december 2023 | 13 min

Josep M. Llovet, MD, PhD - Enhancing Long-Term Survival in Unresectable HCC: Optimizing First-Line Immunotherapy-Based Combination Regimens

18 december 2023 | 12 min

Vishal A. Patel, MD - Making Headway in Treating Resectable Cutaneous Squamous Cell Carcinoma: Setting Sights on Neoadjuvant Immunotherapy

18 december 2023 | 14 min

Patrick Forde, MB, BCh - Keeping the Dialogue Open in Early-Stage NSCLC: Instituting a Multidisciplinary Approach

18 december 2023 | 16 min

Adam Brufsky, MD, PhD - Getting Real With Patients During Clinical Decision-Making: The Value of Sharing Real-World Evidence About CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer

18 december 2023 | 17 min

Wolfgang Miesbach, MD, PhD - Gene Therapy in Hemophilia A: Redefining the Treatment Paradigm

5 december 2023 | 16 min

Jorge Cortes, MD - Third-Line Therapies in Chronic Myeloid Leukemia: Evolving to Overcome the Limitations of Early-Generation Tyrosine Kinase Inhibitors

13 november 2023 | 14 min

Asa Radix, MD, PhD, MPH - A Call to Action to Prevent Cervical Cancer in Transgender and Nonbinary Populations: Patient-Centered Strategies to Increase Screening Rates

31 oktober 2023 | 13 min

Trisha Wise-Draper, MD, PhD - Empowering Precision Decisions: PD-1 Inhibitor-Based Therapies and Biomarker Testing in R/M HNSCC

11 oktober 2023 | 14 min

Richard Finn, MD - Improving Patient Outcomes in Advanced Biliary Tract Cancer: Evaluating the Promise of Immunotherapy Plus Chemotherapy Combinatorial Approaches

25 september 2023 | 14 min

Matthew R. Smith, MD, PhD - Combined Systemic Therapy to Combat Metastatic Hormone-Sensitive Prostate Cancer

22 september 2023 | 9 min

Sapna P. Patel, MD - Enhancing Neoadjuvant and Adjuvant Treatment in Resectable Melanoma: Is Timing the Key to Improved Outcomes?

19 september 2023 | 15 min

Joshua Richter, MD / Saad Z. Usmani, MD, MBA, FACP - Optimizing Patient Outcomes in Relapsed/Refractory Multiple Myeloma: The Role of Novel BCMA-Targeted Bispecific Antibodies

19 september 2023 | 17 min

Alexander I. Spira, MD, PhD, FACP - Breaking News in NSCLC: The Latest Evidence on Emerging Antibody Drug Conjugates Targeting TROP2

5 september 2023 | 15 min

Eric K. Singhi, MD / Charu Aggarwal, MD, MPH - It Takes Two to Tango: Exploring the Clinical Implications of First-Line Immunotherapy Plus Chemotherapy Combinations in Advanced NSCLC

5 september 2023 | 16 min

Jamie E. Chaft, MD - Enhancing Outcomes for Patients With Resected, Early-Stage NSCLC: A Piercing Evaluation of the Clinical Support for Adjuvant Immunotherapies

23 augusti 2023 | 15 min

Stephen Lam Chan, MD - Recalibrating Survival: Available and Recently Approved Immunotherapy-Based Combination Approaches in Unresectable HCC

17 augusti 2023 | 13 min

Enriqueta Felip, MD, PhD / David Harpole, MD - Reflecting on the Role of Perioperative Immunotherapeutic Regimens for Resectable Non–Small-Cell Lung Cancer: Evaluating the Evidence to Determine Better Pathways of Care

27 juli 2023 | 17 min

Eric Jonasch, MD - Optimizing Long-Term Care With Guideline-Recommended Systemic Treatment Options for von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

27 juli 2023 | 14 min

Saad Z. Usmani, MD, MBA, FACP / Gareth J. Morgan, MD, PhD - Strength in Numbers: Triplet Combination Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) Special Patient Populations

7 juli 2023 | 14 min

Ticiana Leal, MD - Inspiring Improved Outcomes in Advanced NSCLC: A Patient-Centered Approach to Integrating Combination Locoregional and Immunotherapy Into Care

3 juli 2023 | 14 min

Miguel-Angel Perales, MD - Shifting Gears in Treating Relapsed and Refractory Indolent B-Cell Lymphomas: Where Do CAR T Cell Therapies Stand in FL and CLL/SLL?

3 juli 2023 | 13 min

Tanios Bekaii-Saab, MD / Kelley A. Rone, DNP, AGNP-c - Providing Holistic Care for Hand-Foot Skin Reaction to Improve Outcomes for Patients on Multikinase Inhibitor Therapy for CRC

27 juni 2023 | 14 min

Axel Hauschild, MD - Advancing Outcomes in Surgically Resectable Cutaneous Squamous Cell Carcinoma: Carving New Paths Forward With Immunotherapies

15 juni 2023 | 13 min

Sara A. Hurvitz, MD, FACP / Miguel Martín, MD, PhD - Integrating Advances in HR+ HER2- Early Breast Cancer: A Focus on Targeted Adjuvant Regimens

15 juni 2023 | 15 min

Javier Cortés, MD / Sarah Donahue, MPH, ANP, AOCNP - Putting Patients First: Optimizing Outcomes via Collaborative Care in Pretreated Advanced Triple Negative Breast Cancer Treatment

12 juni 2023 | 14 min

Dirk Schadendorf, MD - An Evolution in Care for Advanced Melanoma: Exploring the Clinical Implications of Approved and Emerging Anti–LAG-3/PD-1 Combinations

8 juni 2023 | 12 min

Joseph Mikhael, MD, MEd, FRCPC / Paul G. Richardson, MD - Window of Opportunity in Relapsed/Refractory Multiple Myeloma: Is There an Earlier Role for Cereblon (CRBN) E3 Ligase Modulators to Improve Patient Outcomes?

31 maj 2023 | 16 min

Jonathan Schoenfeld, MD, MPH - Evolving the Treatment Landscape in Head and Neck Squamous Cell Carcinoma: Promoting Apoptosis With Emerging Antagonists of Inhibitors of Apoptosis Proteins

31 maj 2023 | 14 min

Suriya Jeyapalan, MD, MPH - Expert Conversations in Newly Diagnosed Glioblastoma: Discussing TTFields as a Recommended Adjuvant Therapeutic Option

23 maj 2023 | 14 min

Hussein Tawbi, MD, PhD / Laura K. Ferris, MD, PhD - Optimizing Outcomes in Advanced Melanoma Through Enhanced Collaboration: A Real-World Multidisciplinary Approach

4 maj 2023 | 15 min

John O. Mascarenhas, MD - Optimizing JAK Inhibitor Therapy for Patients With Myelofibrosis: Integrating New and Emerging Therapies Into the Current Treatment Paradigm

4 maj 2023 | 15 min

Sergio Giralt, MD, FACP, FASTCT - Charting a New Course in the Treatment Paradigm of Relapsed/Refractory Multiple Myeloma: The Current Snapshot of Novel CAR T-Cell Therapies

21 april 2023 | 14 min

Christine E. Jones, BMBS, PhD - A Full-Throated Appeal to Personalize Care in Advanced Gastroesophageal Junction (GEJ) and Esophageal Cancers: Where Do Immunotherapy-Based Regimens Fit In?

10 april 2023 | 14 min

Reinhard Dummer, Prof. Dr. med - Making the Case for a Systemic Approach to Advanced Basal Cell Carcinoma: A Multidisciplinary Team Strategy to Optimize Long-Term Care

30 mars 2023 | 14 min

Giovanni L. Ceresoli - Advancing Care in Advanced Non–Small-Cell Lung Cancer With Combination Locoregional and Systemic Therapies

30 mars 2023 | 15 min

Nicolas Girard, MD, PhD - Fortifying Outcomes in Unresectable Stage III Non–Small-Cell Lung Cancer: Current and Evolving Strategies to Optimize the Use of Consolidation Immunotherapy

15 februari 2023 | 15 min

Richard Finn, MD - Real Talk About CDK4/6 Inhibitors in the Treatment of HR+/HER2- Advanced Breast Cancer: Using Real-World Evidence to Impact Patient Outcomes

15 februari 2023 | 16 min

Ruben A. Mesa, MD, FACP - Risk-Adapted Treatment Algorithms in Myelofibrosis: Optimizing Patient Outcomes With JAK Inhibitors

15 februari 2023 | 14 min

Enriqueta Felip, MD, PhD - Breaking News for Frontline Dual Immunotherapy and Chemotherapy Combination Regimens: Improving Patient Outcomes in Advanced NSCLC

9 januari 2023 | 15 min

Omid Hamid, MD - An Expert Conversation About Anti-LAG-3/PD-1 Combinations: Exploring the Clinical Impact of Approved and Emerging Combinations in the Advanced Melanoma Treatment Landscape

20 december 2022 | 14 min

Todd Schlesinger, MD, FAAD - Optimizing Immunotherapy in Patients With Advanced Basal Cell Carcinoma: Practical Strategies to Inform Care

13 december 2022 | 14 min

Suriya Jeyapalan, MD, MPH - Improving Patient Outcomes in Newly Diagnosed Glioblastoma: A Focus on Novel Adjuvant Therapies

13 december 2022 | 13 min

Charles B. Simone, II, MD, FACRO - Thinking Outside the Box to Advance Cancer Care: The Latest Evidence and Guidance on Novel Portable Electric Field Therapies

17 november 2022 | 15 min

Aditya Bardia, MD, MPH - Reducing Endocrine Resistance in Early Breast Cancer: Will Oral Selective Estrogen Receptor Degraders Provide New Hope?

15 november 2022 | 13 min

Arndt Vogel, MD, PhD - Emerging Trends for Treating Advanced Biliary Tract Cancer: Where Does the Evidence Stand on Immunochemotherapy Combinations

7 november 2022 | 13 min

Eric Jonasch, MD - The Clinical Implications of Current Treatment Options for von Hippel-Lindau Disease

7 november 2022 | 13 min

Samuel L. Washington III, MD, MAS - Bridging the Gap in Prostate Cancer Outcomes for Black Men: Elevating Approaches to Androgen Deprivation Therapy

7 november 2022 | 14 min

Ghassan Abou-Alfa, MD, MBA - Leveraging Combinatorial Approaches in Hepatocellular Carcinoma: An Exploration of the Clinical Implications of the Available Data

28 oktober 2022 | 13 min

Peter R. Galle, MD, PhD - Moving Forward with the Management of Unresectable Hepatocellular Carcinoma: Evaluating the Impact of Emerging First-line Dual Immunotherapy Combination Regimens

28 oktober 2022 | 13 min

Javier Cortés, MD, PhD - BRCA Testing in Patients With Early-Stage Breast Cancer: A Focus on the Patient Conversation

24 oktober 2022 | 11 min

Aiwu Ruth He, MD, PhD - Reshaping the Landscape of Advanced Biliary Tract Cancer: The Evidence for Combination Immunochemotherapy

20 oktober 2022 | 14 min

Joshua Richter, MD - Charting a New Course in Relapsed/Refractory Multiple Myeloma: The Emergence of BCMA-Targeted Therapies

14 oktober 2022 | 12 min

Hope S. Rugo, MD, FASCO - Stay in the Know About HER2-Low: Improving Breast Cancer Outcomes with Emerging Antibody Drug Conjugates

4 oktober 2022 | 14 min

Tanios Bekaii-Saab, MD / Beth McLellan, MD - Managing Hand-Foot Skin Reaction: Interdisciplinary Strategies for Patients on Multikinase Inhibitors

4 oktober 2022 | 16 min

David Paul Carbone, MD, PhD - Big Advances in Resectable Non–Small-Cell Lung Cancer With Neoadjuvant Immunotherapy

3 oktober 2022 | 15 min

Sagar Lonial, MD - Rebooting the Treatment of Relapsed/Refractory Multiple Myeloma: A New Look at Novel Cereblon-Targeted Agents

30 september 2022 | 13 min

Shalina Gupta-Burt, MD - Improving Patient Outcomes in Newly Diagnosed Glioblastoma: Personalizing Treatment and Managing Adverse Events

6 september 2022 | 14 min

Orlando M. Gutierrez, MD - Reducing Disparities in Anemia of CKD Management

5 september 2022 | 14 min

George Kassianos, CBE, MD (Hons), FRCGP - A Vaccinator’s Guide to Viral Vector–Based COVID-19 Vaccines

2 september 2022 | 15 min

Kathleen Moore, MD, MS - Targeting Disease Progression in Advanced Ovarian Cancer: Can Combination PARP Inhibitors and Immune Checkpoint Inhibitors Improve Outcomes?

31 augusti 2022 | 14 min

Antonio González Martin, MD, PhD - Exploring the Evolving Role of PD-1/PD-L1 Inhibitors in Cervical Cancer: Setting Sights on Locally Advanced Disease

31 augusti 2022 | 12 min

Solange Peters, MD, PhD - Harnessing Frontline Dual Immunotherapy and Chemotherapy Combination Regimens for Advanced NSCLC: Strategies to Enhance Individualized Care

23 augusti 2022 | 14 min

Mary O'Brien, MD, FRCP - Moving Immune Checkpoint Inhibitors to Resected Early-Stage Non-Small Cell Lung Cancer: Emerging Strategies for Adjuvant Therapy

12 augusti 2022 | 15 min

Barbara Burtness, MD - Rethinking Therapeutic Strategies for Squamous Cell Carcinoma of the Head and Neck: Promoting Apoptosis with Emerging Therapies

9 augusti 2022 | 14 min

Alexander Drilon, MD - Hitting the Mark in Personalizing Oncology Care: A Clinician’s Guide to Best Practices in Biomarker Testing

2 augusti 2022 | 15 min

Tanios Bekaii-Saab, MD / Kelley A. Rone, DNP, AGNP-c - Providing Holistic Care for Hand-Foot Skin Reaction to Improve Outcomes for Patients on Multikinase Inhibitor Therapy for CRC

Senaste avsnitt

Sebastian Stintzing, MD - A Step-by-Step Guide to Metastatic CRC: Strategies to Integrate Anti-EGFR Therapies

Daniel Petrylak, MD - Answering Key Questions About Biomarkers in Urothelial Cancer: Guidance for Improving Implementation

Benjamin Levy, MD, FASCO - Keeping Pace With TROP2-Directed ADCs: Their Evolving Role in Advanced, Pretreated EGFR-Mutated NSCLC

Luis Paz-Ares, MD, PhD / Niels Reinmuth, MD, PhD - Developing a Master Plan for ES-SCLC: A Practical Guide to Elevate Care in the Real-World

John Marshall, MD - Re-Invigorating the Later-Line Treatment of Metastatic Colorectal Cancer: Practical Strategies to Optimize the Use of Tyrosine Kinase Inhibitors

Neil D. Gross, MD, FACS - Evolving the Multi-Modal Approach for Resectable Cutaneous Squamous Cell Carcinoma: A Multidisciplinary Assessment of Current and Emerging Immunotherapeutic Strategies

Hussein Tawbi, MD, PhD - Evolving Melanoma Care: The Clinical Impact of Anti-LAG-3/PD-1 Combinations

Selim Corbacioglu, MD, PhD - Transforming Transfusion Dependence: Practical Steps for Incorporating Novel Beta Thalassemia Treatments Into Practice

Thomas Powles, MBBS, MRCP, MD / Jonathan E. Rosenberg, MD - Advancing Urothelial Carcinoma Care With Multidisciplinary Strategies for Clinical Management

Barbara Burtness, MD - The Pan-Tumor Perspective: Looking Toward the Future of Care With HER3-Directed ADCs for Pretreated Patients With Advanced Solid Tumors

Mark A. Socinski, MD - Global Perspectives on Biomarker Testing in NSCLC: Clinical Insights on Optimizing Implementation in Practice

Venkataraman Raman Muthusamy, MD, MAS - A Window of Opportunity: Identifying the Risk of Esophageal Adenocarcinoma With Prognostic Testing

Aditya Bardia, MD / Joyce O'Shaughnessy, MD - Optimizing Survivorship Across the Patient Journey, Including Lines of Therapy

Aditya Bardia, MD / Giuseppe Curigliano, MD, PhD - Sequencing in the Real World With Complex Patient Types, Including Underrepresented Populations

Aditya Bardia, MD / Joyce O'Shaughnessy, MD - Expert-Guided Approaches to Sequencing Strategies With ADCs in HR+, HER2- mBC

Jesus G. Berdeja, MD - Optimizing Outcomes in Relapsed/Refractory Multiple Myeloma With Bispecific Antibodies: A Community Clinician's Roadmap

Aditya Bardia, MD / Sara Hurvitz, MD - Making a World of Difference for Patients With HER2-Low and -Ultralow Advanced Breast Cancer: Practical Strategies to Integrate Antibody-Drug Conjugates in Special Populations

Komal Jhaveri, MD, FACP - Opportunities to Personalize Care: Making the Case for TROP2-Directed ADCs in HR+, HER2- Metastatic Breast Cancer

Aditya Bardia, MD / Sara Hurvitz, MD - Realizing the Potential of Antibody-Drug Conjugates in HER2-Low and -Ultralow Advanced Breast Cancer: Evolving Strategies to Individualize Care

Aditya Bardia, MD / Marilyn M. Bui, MD, PhD - Bringing HER2 Low and Ultralow to Light: How to Define and Detect HER2 Status in Advanced Breast Cancer

Thomas Martin, MD - Focusing on the Frontline: The Impact of Anti-CD38-Based Quadruplet Regimens for Transplant-Ineligible, Newly-Diagnosed Myeloma

Arvind Dasari, MD - Leveling Up Care in the Later-Line Treatment of Metastatic Colorectal Cancer: Bringing Quality of Life to the Forefront

Jorge Cortes, MD / Elias Jabbour, MD - Care Strategies for Chronic Myeloid Leukemia in Chronic Phase: Customizing Frontline TKI Therapy to Optimize Long-term Patient Outcomes

Joshua Richter, MD, FACP - Enhancing Outcomes in Heavily Pretreated Relapsed/Refractory Multiple Myeloma: Harnessing Bispecific Antibodies in Community Care

Pasi A. Jänne, MD, PhD - Expanding Pathways of Care for HER2-Positive Metastatic NSCLC: Beyond Mutation to Overexpression

Aditya Bardia, MD - Keeping Pace With TROP2-Directed ADCs in HR-Positive, HER2-Negative/Low Advanced Breast Cancer

Sangini S. Sheth, MD, MPH - The Power of Prevention: Patient-Clinician Insights on Increasing HPV Vaccination Uptake to Reduce Cervical Cancer Risk

Sunandana Chandra, MD, MS - Practical Guidance on Managing Adverse Events Associated With Immunotherapy Regimens for Nonmelanoma Skin Cancers

Alexander I. Spira, MD, PhD, FACP - Biomarkers at the Forefront: The Crucial Role of Testing Across Solid Tumor Types

David Harpole, MD / Alfredo Addeo, MD - The Possibilities of Perioperative: Assessing the Use of Perioperative Immunotherapy for Resectable NSCLC

Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Advancing Care in EGFR-Mutated NSCLC: Unveiling New Horizons With ADCs

David Harpole, MD / Neel Chudgar, MD - The Practicalities of Perioperative Immunotherapy for Resectable NSCLC

David Harpole, MD / Nicolas Girard, MD, PhD - Trials and Tribulations: Examining the Data for Perioperative Immunotherapeutic Approaches in Resectable NSCLC

Jacob Sands, MD / Luis Paz-Ares, MD, PhD - Leveraging Precise Targets to Elevate Outcomes: NSCLC Treatment Strategies for HER2-Directed ADCs

Jia Ruan, MD, PhD - Clinical Case Challenges in Frontline PTCL: Navigating the Landscape of CD30-Positive PTCL Treatment

Nikhil I. Khushalani, MD - Practical Guidance for Advanced, Unresectable Cutaneous Squamous Cell Carcinoma: Using Immunotherapy Effectively in Clinical Practice

Jacob Sands, MD / Raffaele Califano, MD - Novel ADC Targets in Advanced NSCLC: Examining Emerging Strategies for TROP2-Directed ADCs

Vishal A. Patel, MD - Selecting and Sequencing Systemic Treatment for Advanced Basal Cell Carcinoma

Richard Kim, MD / Gerald Prager, MD - Evidence-Based Strategies for Optimizing Long-Term Treatment Responses in Later Lines of mCRC Care

Ahmad Tarhini, MD, PhD - Adjuvant Approaches in High-Risk, Resectable Melanoma: A Practical Guide to Improving Outcomes With Immunotherapy-Based Regimens

Joyce O'Shaughnessy, MD - Harnessing Immunotherapy for Early Breast Cancer Management: Neoadjuvant Updates in HR-Positive, HER2-Negative Disease

David M. Miller, MD, PhD / Todd Schlesinger, MD - A Clinician’s Roadmap to Improving Outcomes in Advanced Basal Cell Carcinoma: Guiding Principles for the Use of Immunotherapies

Mark Awad, MD, PhD - Advancing the Therapeutic Landscape of SCLC with B7-H3–Targeted Antibody-Drug Conjugates: Insights and Future Directions

Vasu Divi, MD, MS - Neoadjuvant Immunotherapy for CSCC: Practical Considerations for Resectability, Patient Selection, and Treatment Optimization

John L. Marshall, MD - Proactive Safety Management Strategies to Extend Survival for Patients With Metastatic CRC

Aditya Bardia, MD - From Theory to Practice: Enhancing Antibody-Drug Conjugate Integration in HER2-Low Advanced Breast Cancer

Rami Komrokji, MD - Navigating the First-Line Treatment Landscape of Anemia in Lower-Risk MDS: Translating the Latest Data to Practice

Stephanie E. Combs, MD / Heather Wakelee, MD - A Growing Need for Targeted Approaches in Unresectable Stage III NSCLC: A Clinical Evaluation of Evolving Data in EGFR Mutation–Positive Disease

Chris Verslype, MD, PhD - Optimizing TKI Therapy for Individualized Advanced HCC Treatment: Taking a Real-World Perspective

Luis Paz-Ares, MD, PhD - Exploring the Potential of TROP2 ADCs for Advanced/Metastatic NSCLC: Implications for Practice

Ticiana Leal, MD - Squaring Off With Squamous NSCLC: The Latest Evidence and Guidance on Chemoimmunotherapy Options

Ghassan Abou-Alfa, MD, MBA - Getting On the Right Tract: Patient-Centered Strategies to Diagnose Biliary Tract Cancers

Paul Telfer, MA, DM, BM, BCh, FRCP, FRCPath - Decoding the Future: Bringing Gene Therapy Into Prime Time for Patients With Sickle Cell Disease

Sagar Lonial, MD, FACP - Accelerating Targeted Degradation in Multiple Myeloma: The Role of CELMoDs in Overcoming IMiD Resistance in Earlier Lines of Therapy

Ben Carpenter, MD, PhD - Exploring Novel Therapeutic Frontiers in Transfusion-Dependent Beta Thalassemia: The Path to Transfusion Independence

Saad Z. Usmani, MD, MBA, FACP, FASCO - Making the Case for Triple Therapy in R/R Multiple Myeloma: Expert Guidance for Optimizing Anti-CD38 mAb Regimens

Josep M. Llovet, MD, PhD - Redefining How to Treat Intermediate-Stage HCC: Exploring TACE Plus Immunotherapy–Based Combination Therapy

Richard Kim, MD - Enhancing Treatment Sequencing to Extend Survival: Tailoring Later-Line Care to the Patient With Metastatic Colorectal Cancer

Jyoti Mayadev, MD - From Routine Screening to Applying Clinical Advances in Locally Advanced Cervical Cancer: Evolving Care in High-Risk Populations

Peter Lio, MD - AI in Healthcare: A Primer for the Practicing Clinician

Peter Lio, MD - Generative AI: Benefits for Your Practice, for Your Patients

Geoffrey Ku, MD, MBA - Conversations in Precision Oncology: Harnessing Testing to Drive Personalized Treatment in HER2-Positive Advanced Gastric Cancer

Martin C. Mahoney, MD, PhD - Reducing the Burden of HPV-Related Cancers: Strategies for Improving HPV Vaccine Uptake in Males

Aditya Bardia, MD - Endocrine Sensitivity in the Real World: Practical Guidance to Optimize Second-Line Care in ER-Positive, HER2-Negative Advanced Breast Cancer

Laura Spring, MD - The Patient-Clinician Alliance to Enhance Care for Patients With Metastatic Breast Cancer on Antibody-Drug Conjugates

Heather Wakelee, MD - Stepping Up Clinical Outcomes for Resectable NSCLC: Examining the Role of Neoadjuvant Plus Adjuvant Immunotherapy Regimens

Sue S. Yom, MD, PhD - Latest Updates in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Clinical Potential of Inhibitor of Apoptosis Protein (IAP) Antagonists to Change the Treatment Landscape

Steven M. Horwitz, MD - Advancing The Treatment Paradigm in Relapsed/Refractory B- and T-Cell Lymphoma: The Evolving Role of EZH1/2 Pathway Inhibitors

Nikhil I. Khushalani, MD - Pointing the Way to Enhanced Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Practical Strategies to Incorporate Neoadjuvant Immunotherapy

Stephen M. Ansell, MD, PhD / Caron Jacobson, MD, MMSc - Navigating a New Treatment Algorithm for Patients With Relapsed/Refractory Follicular Lymphoma: Where Do CD20 x CD3 Bispecific Antibodies Fit In?

Susana M. Campos, MD, MPH - Expanding the Potential of HER2-Directed Antibody-Drug Conjugates: Evidence and Application in New Tumor Types

John N. Allan, MD - Enhancing Patient Outcomes in Relapsed/Refractory Follicular Lymphoma: Recognizing the Role of Novel Bispecific Antibody–Based Therapies

Evan J. Lipson, MD - Real Talk About Maximizing Care in Advanced Melanoma: Balancing Benefit and Risk Using Dual Immunotherapy Regimens

Peter R. Galle, MD, PhD - Assembling a Long-Term Sequential Plan for Unresectable HCC: Practical Guidance for Improving Real-World Outcomes

David M. Miller, MD, PhD / Kevin Emerick, MD - Coming Together to Improve Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Multidisciplinary Care Strategies With Neoadjuvant Immunotherapy

Tanya Siddiqi, MD - Addressing Patient Needs With CAR T-Cell Therapy in the Treatment of CLL/SLL: Preparing for an Evolving Treatment Paradigm

Manish A. Shah, MD - Keeping Current on Frontline Immunotherapy-Chemotherapy Combinations: HER2-Positive and HER2-Negative Unresectable Advanced Gastric or GEJ Adenocarcinoma

Josep M. Llovet, MD, PhD - Enhancing Long-Term Survival in Unresectable HCC: Optimizing First-Line Immunotherapy-Based Combination Regimens